These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25875973)

  • 1. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
    Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
    Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
    Bryant BJ; Im K; Broome DR
    Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
    Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
    Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
    Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
    Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
    Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
    Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.
    Abujudeh HH; Rolls H; Kaewlai R; Agarwal S; Gebreananya ZA; Saini S; Schaefer PW; Kay J
    J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of immediate gadolinium contrast media reactions.
    Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
    AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease.
    Martin DR; Kalb B; Mittal A; Salman K; Vedantham S; Mittal PK
    Radiology; 2018 Jan; 286(1):113-119. PubMed ID: 28731375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.
    Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P
    Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
    Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA
    Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Safety of Intravenous Gadolinium-enhanced MRI in Patients Following Liver Transplantation.
    Flynn MM; Parekh AN; Parikh MR; Sood A; Shaffer KM; Runge TM; Lipowska AM; Perez SD; Sakaria SS; Subramanian RM
    Transplantation; 2019 Jun; 103(6):e159-e163. PubMed ID: 30801544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations.
    de Campos RO; Heredia V; Ramalho M; De Toni MS; Lugo-Somolinos A; Fuller ER; Semelka RC
    AJR Am J Roentgenol; 2011 Mar; 196(3):545-52. PubMed ID: 21343495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
    Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
    JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
    Soyer P; Dohan A; Patkar D; Gottschalk A
    J Magn Reson Imaging; 2017 Apr; 45(4):988-997. PubMed ID: 27726239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.
    McWilliams RG; Frabizzio JV; De Backer AI; Grinberg A; Maes BD; Zobel BB; Gottschalk A
    J Magn Reson Imaging; 2020 Feb; 51(2):607-614. PubMed ID: 31287213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.
    Starekova J; Bruce RJ; Sadowski EA; Reeder SB
    Radiology; 2020 Dec; 297(3):556-562. PubMed ID: 32990511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries.
    Gerretsen SC; le Maire TF; Miller S; Thurnher SA; Herborn CU; Michaely HJ; Kramer H; Vanzulli A; Vymazal J; Wasser MN; Ballarati CE; Kirchin MA; Pirovano G; Leiner T
    Radiology; 2010 Jun; 255(3):988-1000. PubMed ID: 20501735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.